☆ 4.7 Article

Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer

EUROPEAN JOURNAL OF CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021

Sundeep Agrawal et al.

Summary: Single-arm trials have been used to expedite access to transformative therapies, but there are challenges in using them for drug approval. A large number of approvals have been based on single-arm trials, with response rate as the most common endpoint. However, there are limitations and careful considerations required.

JAMA ONCOLOGY (2023)

添加到收藏夹

Editorial Material Oncology

Real World Data- Does it Cut the Mustard or Should We Take it With a Pinch of Salt?

R. Muirhead et al.

CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Marketing Authorization Applications Made to the European Medicines Agency in 2018-2019: What was the Contribution of Real-World Evidence?

Robert Flynn et al.

Summary: The study found that RWE is widely used to support the evaluation of MAAs and EOIs submitted to the EMA, with registries and hospital data being the main sources. RWE is primarily used to support the safety and efficacy of drugs, with cohort studies being the most commonly used study design.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Oncology

The value of anticancer drugs - a regulatory view

Francesco Pignatti et al.

Summary: This paper discusses the understanding and measurement of drug value in oncology from the perspectives of different decision makers, including regulators, payers, patients, and clinicians. Although a unique definition capturing the concept of value is unlikely to emerge, the importance of understanding different viewpoints and how regulators can help inform different decision makers is discussed.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Real-World Evidence - Where Are We Now?

John Concato et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Oncology

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

David C. de Leeuw et al.

Summary: The treatment of elderly patients with acute myeloid leukemia is a challenge due to patient diversity and disease heterogeneity. Determining fitness and selecting appropriate treatments based on factors like age, performance status, and comorbidities is important. Recent developments such as the addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and improved formulations of existing drugs have improved treatment outcomes. Selecting patient-tailored treatments based on fitness and disease biology is essential.

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Review Oncology

Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas-Looking Forward

Alexandra C. Istl et al.

Summary: This review summarizes the current evidence on neoadjuvant radiotherapy and systemic therapy for retroperitoneal sarcoma (RPS) and suggests that these treatments may provide benefits in certain clinical scenarios. The importance of a histology-specific approach to RPS research is highlighted, and future directions of study are discussed.

CANCERS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Natural History and Real-World Data in Rare Diseases: Applications, Limitations, and Future Perspectives

Jing Liu et al.

Summary: This article introduces the unique challenges in understanding rare diseases and drug development for these conditions, emphasizing the important role of natural history data and real-world data. It discusses the opportunities for cross-sector collaboration and the use of new technologies in data collection and evidence generation.

JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Article

Increasing Inclusiveness of Patient-Centric Clinical Evidence Generation in Oncology: Real-World Data and Clinical Trials

Jennifer H. Benbow et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)

添加到收藏夹

Article Medicine, General & Internal

Heterogeneity in pragmatic randomised trials: sources and management

Bruno Giraudeau et al.

Summary: Pragmatic trials aim to generate evidence to inform decisions, but heterogeneity in patient characteristics and other factors can affect outcomes. Different sources of heterogeneity in trials should be managed, and some heterogeneity can be acceptable. Heterogeneity in centers and patients should be welcomed, control interventions should reflect usual care, and flexibility in interventions should be allowed. Objective outcomes and intention-to-treat analysis should be favored. Process analyses can provide further understanding of trial results.

BMC MEDICINE (2022)

添加到收藏夹

Review Medical Informatics

Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation

Alfredo Aram Pulini et al.

Summary: Real-world data (RWD) and real-world evidence (RWE) are viewed as complementary to traditional randomized controlled trials (RCT), with potential value in market authorization discussions and price negotiations, but they have methodological limitations. The misuse of terms is common, and the value of these data can vary greatly depending on the characteristics of each product, making them more of a useful rather than indispensable tool.

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Methods of Public Health Research - Strengthening Causal Inference from Observational Data

Miguel A. Hernan

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer

Robbe Saesen et al.

Summary: EORTC has conducted 113 Treatment Optimisation Studies (TOSs) in the past four decades, mainly focusing on international, multicentre phase III trials comparing pharmacological combination regimens against standard-of-care treatments in terms of improving overall survival of cancer patients. Although typically supported by the industry, their legal sponsor is generally an independent party that does not benefit monetarily from the outcomes.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Can real-world data really replace randomised clinical trials?

Sreeram V. Ramagopalan et al.

BMC MEDICINE (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

The Magic of Randomization versus the Myth of Real-World Evidence

Rory Collins et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Oncology

Real-World Evidence in Oncology: Opportunities and Limitations

Massimo Di Maio et al.

ONCOLOGIST (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making

Robbe Saesen et al.

FRONTIERS IN PHARMACOLOGY (2020)

添加到收藏夹

Article Health Care Sciences & Services

The trials within cohorts design facilitated efficient patient enrollment and generalizability in oncology setting

Alice M. Couwenberg et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)

添加到收藏夹

Editorial Material Public, Environmental & Occupational Health

Benchmarking Observational Methods by Comparing Randomized Trials and Their Emulations

Issa J. Dahabreh et al.

EPIDEMIOLOGY (2020)

添加到收藏夹

Article Oncology

Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

Sylvie Bonvolot et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Editorial Material Oncology

Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence

Safiya Karim et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Real-world data: towards achieving the achievable in cancer care

Christopher M. Booth et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe

Alison Cave et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Editorial Material Medicine, General & Internal

Real-world studies no substitute for RCTs in establishing efficacy

Hertzel C. Gerstein et al.

LANCET (2019)

添加到收藏夹

Article Health Care Sciences & Services

Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust

Elisabeth M. Oehrlein et al.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2019)

添加到收藏夹

Article Health Care Sciences & Services

The RCT augmentation: a novel simulation method to add patient heterogeneity into phase III trials

Helene Karcher et al.

BMC MEDICAL RESEARCH METHODOLOGY (2018)

添加到收藏夹

Article Oncology

The use of real-world data in cancer drug development

E. Skovlund et al.

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Article Health Care Sciences & Services

Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines

Lisette Pregelj et al.

HEALTH AFFAIRS (2018)

添加到收藏夹

Article Medicine, General & Internal

Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation

Alexandra Pacurariu et al.

BMJ OPEN (2018)

添加到收藏夹

Article Oncology

'Mind the gap' between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research

Emmanuelle Kempf et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Editorial Material Oncology

Real-world data for efficient health technology assessment

Peter S. Hall

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Real-world Data for Clinical Evidence Generation in Oncology

Sean Khozin et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

添加到收藏夹

Review Economics

What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews

Amr Makady et al.

VALUE IN HEALTH (2017)

添加到收藏夹

Article Medicine, General & Internal

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

Courtney Davis et al.

BMJ-BRITISH MEDICAL JOURNAL (2017)

添加到收藏夹

Article Medicine, General & Internal

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

Courtney Davis et al.

BMJ-BRITISH MEDICAL JOURNAL (2017)

添加到收藏夹

Article Oncology

Real-world Data for Clinical Evidence Generation in Oncology

Sean Khozin et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?

Jessica M. Franklin et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Article Public, Environmental & Occupational Health

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available

Miguel A. Hernan et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)

添加到收藏夹

Article Health Care Sciences & Services

Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses

Miguel A. Hernan et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)

添加到收藏夹

Letter Oncology

Can Observational Data Replace Randomized Trials?

Paul McGale et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Review Medicine, General & Internal

Pragmatic Trials

Ian Ford et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Editorial Material Medicine, General & Internal

Real-World Evidence - What Is It and What Can It Tell Us?

Rachel E. Sherman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Editorial Material Oncology

Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence

C. M. Booth et al.

BRITISH JOURNAL OF CANCER (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

Explanatory trials versus pragmatic trials

Philip Sedgwick

BMJ-BRITISH MEDICAL JOURNAL (2014)

添加到收藏夹

Article

Health-Related Quality of Life in EORTC clinical trials — 30 years of progress from methodological developments to making a real impact on oncology practice

G. Velikova et al.

EJC SUPPLEMENTS (2012)

添加到收藏夹

Article Medicine, General & Internal

Rethinking pragmatic randomised controlled trials: introducing the cohort multiple randomised controlled trial design

Clare Relton et al.

BMJ-BRITISH MEDICAL JOURNAL (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.